Sepracor, Inc. Presents Safety Data on OMNARIS(TM) AQ and OMNARIS(TM) HFA Nasal Sprays at American Academy of Allergy, Asthma and Immunology (AAAAI)

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) announced today that new data were presented that reinforce prior research findings regarding the low systemic bioavailability of ciclesonide, the active ingredient in OMNARIS (ciclesonide) AQ Nasal Spray, a product approved by the U.S. Food and Drug Administration, and is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergies. These new data were presented at the AAAAI 2008 annual meeting held in Philadelphia, PA.